{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:07:33Z","timestamp":1791925653886,"version":"4.3.4"},"reference-count":103,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Patras"},{"name":"Hellenic State Scholarships Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Azithromycin has become famous in the last two years, not for its main antimicrobial effect, but for its potential use as a therapeutic agent for COVID-19 infection. Initially, there were some promising results that supported its use, but it has become clear that scientific results are insufficient to support such a positive assessment. In this review we will present all the literature data concerning the activity of azithromycin as an antimicrobial, an anti-inflammatory, or an antivirus agent. Our aim is to conclude whether its selection should remain as a valuable antivirus agent or if its use simply has an indirect therapeutic contribution due to its antimicrobial and\/or immunomodulatory activity, and therefore, if its further use for COVID-19 treatment should be interrupted. This halt will prevent further antibiotic resistance expansion and will keep azithromycin as a valuable anti-infective therapeutic agent.<\/jats:p>","DOI":"10.3390\/antibiotics11081063","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T21:03:50Z","timestamp":1659906230000},"page":"1063","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Azithromycin through the Lens of the COVID-19 Treatment"],"prefix":"10.3390","volume":"11","author":[{"given":"Georgia G.","family":"Kournoutou","sequence":"first","affiliation":[{"name":"Department of Biochemistry, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-7408","authenticated-orcid":false,"given":"George","family":"Dinos","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bph.13936","article-title":"The Macrolide Antibiotic Renaissance","volume":"174","author":"Dinos","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.32.5.752","article-title":"In Vitro Activities of Azithromycin (CP 62,993), Clarithromycin (A-56268; TE-031), Erythromycin, Roxithromycin, and Clindamycin","volume":"32","author":"Barry","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s100960100532","article-title":"Relative Potency of Telithromycin, Azithromycin and Erythromycin against Recent Clinical Isolates of Gram-Positive Cocci","volume":"20","author":"Barry","year":"2001","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"ref_4","first-page":"445","article-title":"Comparative in Vitro Potencies of Nine New Macrolides","volume":"14","author":"Fernandes","year":"1988","journal-title":"Drugs Exp. Clin. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/jac\/23.3.299","article-title":"The Development of Macrolides and Related Compounds","volume":"23","author":"Wise","year":"1989","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The Pharmacokinetics of Azithromycin in Human Serum and Tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/25.suppl_A.83","article-title":"Relationship of High Tissue Concentrations of Azithromycin to Bactericidal Activity and Efficacy in Vivo","volume":"25","author":"Retsema","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0732-8893(92)90055-X","article-title":"Clarithromycin, a Unique Macrolide. A Pharmacokinetic, Microbiological, and Clinical Overview","volume":"15","author":"Hardy","year":"1992","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_9","first-page":"356","article-title":"Distribution of Orally Administered Azithromycin in Various Blood Compartments","volume":"32","author":"Wildfeuer","year":"1994","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/dkab404","article-title":"Azithromycin in Patients with COVID-19: A Systematic Review and Meta-Analysis","volume":"77","author":"Ayerbe","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.2021.11517","article-title":"Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial","volume":"326","author":"Oldenburg","year":"2021","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/35101544","article-title":"Structural Basis for the Interaction of Antibiotics with the Peptidyl Transferase Centre in Eubacteria","volume":"413","author":"Zarivach","year":"2001","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17158","DOI":"10.1073\/pnas.1008685107","article-title":"Revisiting the Structures of Several Antibiotics Bound to the Bacterial Ribosome","volume":"107","author":"Bulkley","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17152","DOI":"10.1073\/pnas.1007988107","article-title":"Structures of the Escherichia Coli Ribosome with Antibiotics Bound near the Peptidyl Transferase Center Explain Spectra of Drug Action","volume":"107","author":"Dunkle","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1261\/rna.069260.118","article-title":"High-Resolution Crystal Structures of Ribosome-Bound Chloramphenicol and Erythromycin Provide the Ultimate Basis for Their Competition","volume":"25","author":"Svetlov","year":"2019","journal-title":"RNA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15958","DOI":"10.1073\/pnas.1417334111","article-title":"The General Mode of Translation Inhibition by Macrolide Antibiotics","volume":"111","author":"Kannan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","article-title":"How Macrolide Antibiotics Work","volume":"43","author":"Mankin","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1038\/s41467-021-24674-9","article-title":"Structural and Mechanistic Basis for Translation Inhibition by Macrolide and Ketolide Antibiotics","volume":"12","author":"Beckert","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jac\/dkn427","article-title":"Different Effects of Telithromycin on MUC5AC Production Induced by Human Neutrophil Peptide-1 or Lipopolysaccharide in NCI-H292 Cells Compared with Azithromycin and Clarithromycin","volume":"63","author":"Ishimoto","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","unstructured":"Omura, S. (2022). Macrolides in clinical practice. Macrolide Antibiotics: Chemistry, Biology and Practice, Academic Press. [1st ed.]."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112739","DOI":"10.1016\/j.ejmech.2020.112739","article-title":"Azithromycin: The First Broad-Spectrum Therapeutic","volume":"207","author":"Firth","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/AAC.47.7.2199-2203.2003","article-title":"Tolerability of Azithromycin as Malaria Prophylaxis in Adults in Northeast Papua, Indonesia","volume":"47","author":"Taylor","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: Mechanisms of Action and Their Relevance for Clinical Applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_24","unstructured":"WHO (2022, February 15). WHO Model List of Essential Medicines - 22nd List. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2021.02."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of Azithromycin on Asthma Exacerbations and Quality of Life in Adults with Persistent Uncontrolled Asthma (AMAZES): A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_26","first-page":"CD011825","article-title":"Adverse Events in People Taking Macrolide Antibiotics versus Placebo for Any Indication","volume":"18","author":"Hansen","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","article-title":"The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms","volume":"9","author":"Zimmermann","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of Survival in Patients with Diffuse Panbronchiolitis Treated with Low-Dose Erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: From in Vitro Anti-Inflammatory and Immunomodulatory Properties to Clinical Practice in Respiratory Diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.biopha.2018.11.090","article-title":"Azithromycin Treats Diffuse Panbronchiolitis by Targeting T Cells via Inhibition of MTOR Pathway","volume":"110","author":"Weng","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.ftd.0000195617.69721.a5","article-title":"Pharmacokinetics of Azithromycin in Plasma, Blood, Polymorphonuclear Neutrophils and Sputum during Long-Term Therapy in Patients with Cystic Fibrosis","volume":"28","author":"Wilms","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2163","DOI":"10.1002\/rmv.2163","article-title":"Azithromycin in Viral Infections","volume":"31","author":"Oliver","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","article-title":"Immunomodulation by Macrolides: Therapeutic Potential for Critical Care","volume":"8","author":"Reijnders","year":"2020","journal-title":"Lancet. Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejphar.2010.06.056","article-title":"Azithromycin Inhibits Nontypeable Haemophilus Influenzae-Induced MUC5AC Expression and Secretion via Inhibition of Activator Protein-1 in Human Airway Epithelial Cells","volume":"644","author":"Araki","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.200711-1666OC","article-title":"Azithromycin Improves Macrophage Phagocytic Function and Expression of Mannose Receptor in Chronic Obstructive Pulmonary Disease","volume":"178","author":"Hodge","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1465-9921-13-83","article-title":"Leaky Lysosomes in Lung Transplant Macrophages: Azithromycin Prevents Oxidative Damage","volume":"13","author":"Persson","year":"2012","journal-title":"Respir. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/jac\/dkn007","article-title":"Azithromycin Alters Macrophage Phenotype","volume":"61","author":"Murphy","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1465-9921-7-134","article-title":"Azithromycin Reduces Spontaneous and Induced Inflammation in DeltaF508 Cystic Fibrosis Mice","volume":"7","author":"Legssyer","year":"2006","journal-title":"Respir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7150\/ijbs.5.667","article-title":"Azithromycin Suppresses Interleukin-12p40 Expression in Lipopolysaccharide and Interferon-Gamma Stimulated Macrophages","volume":"5","author":"Yamauchi","year":"2009","journal-title":"Int. J. Biol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1183\/09031936.06.00001506","article-title":"Azithromycin Increases Phagocytosis of Apoptotic Bronchial Epithelial Cells by Alveolar Macrophages","volume":"28","author":"Hodge","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/AAC.47.1.48-53.2003","article-title":"Fourteen-Member Macrolides Promote the Phosphatidylserine Receptor-Dependent Phagocytosis of Apoptotic Neutrophils by Alveolar Macrophages","volume":"47","author":"Yamaryo","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jdermsci.2016.07.007","article-title":"Azithromycin Impairs TLR7 Signaling in Dendritic Cells and Improves the Severity of Imiquimod-Induced Psoriasis-like Skin Inflammation in Mice","volume":"84","author":"Huang","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin Modulates Neutrophil Function and Circulating Inflammatory Mediators in Healthy Human Subjects","volume":"450","author":"Cepelak","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1034\/j.1399-3003.2000.15e08.x","article-title":"Effects of Azithromycin on Ozone-Induced Airway Neutrophilia and Cytokine Release","volume":"15","author":"Criqui","year":"2000","journal-title":"Eur. Respir. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/pupt.1998.0123","article-title":"Function of Human Alveolar Macrophages after a 3-Day Course of Azithromycin in Healthy Volunteers","volume":"11","author":"Aubert","year":"1998","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_46","first-page":"CD002203","article-title":"Macrolide Antibiotics for Cystic Fibrosis","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane database Syst. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ppul.21613","article-title":"Clarithromycin Therapy for Patients with Cystic Fibrosis: A Randomized Controlled Trial","volume":"47","author":"Robinson","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12016","DOI":"10.1038\/srep12016","article-title":"Azithromycin Inhibits IL-1 Secretion and Non-Canonical Inflammasome Activation","volume":"5","author":"Gualdoni","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/embo-reports\/kve062","article-title":"Structural Basis for Selectivity and Toxicity of Ribosomal Antibiotics","volume":"2","author":"Springer","year":"2001","journal-title":"EMBO Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for Prevention of Exacerbations in Severe Asthma (AZISAST): A Multicentre Randomised Double-Blind Placebo-Controlled Trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin Induces Anti-Viral Responses in Bronchial Epithelial Cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_52","first-page":"2121","article-title":"Influenzae Potentiates Airway Epithelial Cell Responses to Rhinovirus by Increasing ICAM-1 and TLR3 Expression","volume":"20","author":"Sajjan","year":"2006","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1164\/rccm.201809-1739OC","article-title":"Long-Term Azithromycin Reduces Haemophilus Influenzae and Increases Antibiotic Resistance in Severe Asthma","volume":"200","author":"Taylor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2000194","DOI":"10.1183\/13993003.00194-2020","article-title":"Airway Abundance of Haemophilus Influenzae Predicts Response to Azithromycin in Adults with Persistent Uncontrolled Asthma","volume":"56","author":"Taylor","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1183\/09031936.00102014","article-title":"Novel Antiviral Properties of Azithromycin in Cystic Fibrosis Airway Epithelial Cells","volume":"45","author":"Kopf","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","article-title":"Azithromycin, a 15-Membered Macrolide Antibiotic, Inhibits Influenza A(H1N1)Pdm09 Virus Infection by Interfering with Virus Internalization Process","volume":"72","author":"Tran","year":"2019","journal-title":"J. Antibiot. (Tokyo)."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14408","DOI":"10.1073\/pnas.1618029113","article-title":"Zika Virus Cell Tropism in the Developing Human Brain and Inhibition by Azithromycin","volume":"113","author":"Retallack","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola Virus Inhibitors for Drug Repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpt.1857","article-title":"Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19","volume":"108","author":"Damle","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"28698","DOI":"10.1038\/srep28698","article-title":"Azithromycin Induces Anti-Viral Effects in Cultured Bronchial Epithelial Cells from COPD Patients","volume":"6","author":"Menzel","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijantimicag.2018.12.009","article-title":"Spiramycin and Azithromycin, Safe for Administration to Children, Exert Antiviral Activity against Enterovirus A71 in Vitro and in Vivo","volume":"53","author":"Zeng","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: Recent Insights into Emerging Coronaviruses","volume":"14","author":"Falzarano","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19 - Preliminary Report. Reply","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet (Lond. Engl. )"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104228","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In Vitro Testing of Combined Hydroxychloroquine and Azithromycin on SARS-CoV-2 Shows Synergistic Effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"13093","DOI":"10.1038\/s41598-020-70143-6","article-title":"In Vitro Screening of a FDA Approved Chemical Library Reveals Potential Inhibitors of SARS-CoV-2 Replication","volume":"10","author":"Touret","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Gyselinck, I., Janssens, W., Verhamme, P., and Vos, R. (2021). Rationale for Azithromycin in COVID-19: An Overview of Existing Evidence. BMJ open Respir. Res., 8.","DOI":"10.1136\/bmjresp-2020-000806"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","article-title":"Hydroxychloroquine Use against SARS-CoV-2 Infection in Non-Human Primates","volume":"585","author":"Maisonnasse","year":"2020","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Albani, F., Fusina, F., Giovannini, A., Ferretti, P., Granato, A., Prezioso, C., Divizia, D., Sabaini, A., Marri, M., and Malpetti, E. (2020). Impact of Azithromycin and\/or Hydroxychloroquine on Hospital Mortality in COVID-19. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092800"},{"key":"ref_73","first-page":"396","article-title":"Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19","volume":"97","author":"Arshad","year":"2020","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"106143","DOI":"10.1016\/j.ijantimicag.2020.106143","article-title":"Safety and Effectiveness of Azithromycin in Patients with COVID-19: An Open-Label Randomised Trial","volume":"56","author":"Sekhavati","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/cts.12860","article-title":"Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19","volume":"13","author":"Lauriola","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3906\/sag-2005-82","article-title":"Hydroxychloroquine plus Azithromycin and Early Hospital Admission Are Beneficial in COVID-19 Patients: Turkish Experience with Real-Life Data","volume":"51","author":"Yildirim","year":"2021","journal-title":"Turkish J. Med. Sci."},{"key":"ref_77","first-page":"15","article-title":"Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild\/Moderate COVID-19","volume":"18","author":"Thomas","year":"2020","journal-title":"Asian J. Med. Heal."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical Impact of COVID-19 on Patients with Cancer (CCC19): A Cohort Study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s11739-020-02505-x","article-title":"The Association of Treatment with Hydroxychloroquine and Hospital Mortality in COVID-19 Patients","volume":"15","author":"Ayerbe","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_82","first-page":"478","article-title":"Response to Correspondence Concerning: \u201cEarly Hydroxychloroquine but Not Chloroquine Use Reduces ICU Admission in COVID-19 Patients\u201d","volume":"103","author":"Lammers","year":"2021","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2258","DOI":"10.1002\/rmv.2258","article-title":"Efficacy and Safety of Azithromycin in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"32","author":"Kamel","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","article-title":"Azithromycin in the Treatment of COVID-19: A Review","volume":"19","author":"Horcajada","year":"2021","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"101906","DOI":"10.1016\/j.tmaid.2020.101906","article-title":"Risk of Hospitalization for COVID-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis","volume":"38","author":"Wolkoff","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in Addition to Standard of Care versus Standard of Care Alone in the Treatment of Patients Admitted to the Hospital with Severe COVID-19 in Brazil (COALITION II): A Randomised Clinical Trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"(2021). Azithromycin for Community Treatment of Suspected COVID-19 in People at Increased Risk of an Adverse Clinical Course in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial. Lancet (Lond. Engl.), 397, 1063\u20131074.","DOI":"10.1016\/S0140-6736(21)00461-X"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s13063-020-04593-8","article-title":"A Multi-Centre Open-Label Two-Arm Randomised Superiority Clinical Trial of Azithromycin versus Usual Care in Ambulatory COVID-19: Study Protocol for the ATOMIC2 Trial","volume":"21","author":"Hinks","year":"2020","journal-title":"Trials"},{"key":"ref_90","unstructured":"(2021). Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial. Lancet (Lond. Engl.), 397, 1637\u20131645."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Bogdani\u0107, N., Mo\u010dibob, L., Vidovi\u0107, T., Soldo, A., and Begova\u0107, J. (2022). Azithromycin Consumption during the COVID-19 Pandemic in Croatia, 2020. PLoS One, 17.","DOI":"10.1371\/journal.pone.0263437"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cid\/ciab225","article-title":"Trends in Prescribing of Antibiotics and Drugs Investigated for Coronavirus Disease 2019 (COVID-19) Treatment in US Nursing Home Residents During the COVID-19 Pandemic","volume":"74","author":"Gouin","year":"2022","journal-title":"Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Stoichitoiu, L.E., Pinte, L., Ceasovschih, A., Cernat, R.C., Vlad, N.D., Padureanu, V., Sorodoc, L., Hristea, A., Purcarea, A., and Badea, C. (2022). In-Hospital Antibiotic Use for COVID-19: Facts and Rationales Assessed through a Mixed-Methods Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113194"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","article-title":"Antimicrobial Resistance: A Global Multifaceted Phenomenon","volume":"109","author":"Prestinaci","year":"2015","journal-title":"Pathog. Glob. Health"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1038\/s41598-019-42423-3","article-title":"Azithromycin Resistance Levels and Mechanisms in Escherichia Coli","volume":"9","author":"Gomes","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_96","unstructured":"Graham, J.D., and Rickwoods, E. (1996). Ribosomes and Polysomes. Subcellular Fractionation. A Practical Approach, IRL Press at Oxford University Press."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","article-title":"Co-Infections in People with COVID-19: A Systematic Review and Meta-Analysis","volume":"81","author":"Lansbury","year":"2020","journal-title":"J. Infect."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2012.194139","article-title":"Bacterial Coinfection in Influenza: A Grand Rounds Review","volume":"309","author":"Chertow","year":"2013","journal-title":"JAMA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/17476348.2020.1730180","article-title":"Assessment of Efficacy of Oseltamivir-Azithromycin Combination Therapy in Prevention of Influenza-A (H1N1)Pdm09 Infection Complications and Rapidity of Symptoms Relief","volume":"14","author":"Ishaqui","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2017.05.008","article-title":"Anti-Inflammatory Effects of Adjunctive Macrolide Treatment in Adults Hospitalized with Influenza: A Randomized Controlled Trial","volume":"144","author":"Lee","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Segala, F.V., Bavaro, D.F., Di Gennaro, F., Salvati, F., Marotta, C., Saracino, A., Murri, R., and Fantoni, M. (2021). Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review. Viruses, 13.","DOI":"10.3390\/v13112110"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Pinte, L., Ceasovschih, A., Niculae, C.-M., Stoichitoiu, L.E., Ionescu, R.A., Balea, M.I., Cernat, R.C., Vlad, N., Padureanu, V., and Purcarea, A. (2022). Antibiotic Prescription and In-Hospital Mortality in COVID-19: A Prospective Multicentre Cohort Study. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060877"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1063\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:04:34Z","timestamp":1760141074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":103,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["antibiotics11081063"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11081063","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]}}}